Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.35 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10063796 | 0.92 | ALDH1A1 (0.44) | ALDH1A1CYP2D6HPGDKDM4ETP53 | |
| SCHEMBL12308922 | 0.92 | ALDH1A1 (0.44) | ALDH1A1CYP2D6HPGDKDM4ETP53 | |
| SCHEMBL5935950 | 0.88 | ALDH1A1 (0.40) | ALDH1A1CYP2D6HPGDKDM4ETP53 | |
| SCHEMBL866981 | 0.88 | ALDH1A1 (0.44) | ALDH1A1CYP2D6HPGDKDM4ELMNA | |
| SCHEMBL12087618 | 0.87 | ALDH1A1 (0.41) | ALDH1A1CYP2D6HPGDKDM4ETP53 | |
| SCHEMBL15134282 | 0.87 | ALDH1A1 (0.41) | ALDH1A1CYP2D6HPGDKDM4ETP53 | |
| SCHEMBL12222648 | 0.87 | ALDH1A1 (0.41) | ALDH1A1CYP2D6MAPTCA12CA1 | |
| SCHEMBL264599 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CYP2D6HPGDLMNAHSD17B10 | |
| SCHEMBL17212355 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CYP2D6HPGDKDM4ELMNA | |
| SCHEMBL12254969 | 0.86 | ALDH1A1 (0.40) | ALDH1A1CYP2D6HPGDKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619007-A1 | COMPOSITIONS FOR ATTENUATING ANTI-INFECTIVE RESISTANCE, USES AND METHODS THEREOF | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-09-24 | — | — | EP | claimed |
| US-20250205275-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-06-26 | — | — | US | claimed |
| EP-4499113-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-02-05 | — | — | EP | claimed |
| WO-2024103182-A1 | COMPOSITIONS FOR ATTENUATING ANTI-INFECTIVE RESISTANCE, USES AND METHODS THEREOF | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2024-05-23 | — | — | WO | claimed |
| WO-2023178445-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2023-09-28 | — | — | WO | claimed |
| US-11059785-B2 | Polymeric metal chelating compositions and methods of preparing same for controlling growth and activities of living cells and organisms | CHELATION PARTNERS INCORPORATED (CA) | 2021-07-13 | — | — | US | claimed |
| EP-3504188-A1 | POLYMERIC METAL CHELATING COMPOSITIONS AND METHODS OF PREPARING SAME FOR CONTROLLING GROWTH AND ACTIVITIES OF LIVING CELLS AND ORGANISMS | Chelation Partners Incorporated (CA) | 2019-07-03 | — | — | EP | claimed |
| WO-2018035613-A1 | POLYMERIC METAL CHELATING COMPOSITIONS AND METHODS OF PREPARING SAME FOR CONTROLLING GROWTH AND ACTIVITIES OF LIVING CELLS AND ORGANISMS | CHELATION PARTNERS INCORPORATED (CA) | 2018-03-01 | — | — | WO | claimed |
| WO-2025204124-A1 | METHOD FOR PRODUCING POLYMER | ＡＧＣ株式会社 | 2025-10-02 | — | — | WO | disclosed |
| EP-4619007-A1 | COMPOSITIONS FOR ATTENUATING ANTI-INFECTIVE RESISTANCE, USES AND METHODS THEREOF | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-09-24 | — | — | EP | disclosed |
| US-20250205275-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-06-26 | — | — | US | disclosed |
| CN-119763890-A | Surface-functionalized dry ion conductor and preparation method and application thereof | 华南理工大学 | 2025-04-04 | — | — | CN | disclosed |
| EP-4499113-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | FE PHARMACEUTICALS (CANADA) INC. (CA) | 2025-02-05 | — | — | EP | disclosed |
| WO-2024162296-A1 | POLYVINYL ALCOHOL-BASED POLYMER | 日本酢ビ・ポバール株式会社 | 2024-08-08 | — | — | WO | disclosed |
| US-20100317816-A1 | Biomedical devices | BAUSCH & LOMB INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| US-20100136353-A1 | AQUEOUS OLIGOMER / POLYMER EMULSION WITH CATIONIC FUNCTIONALITY | DSM IP ASSETS B.V. (NL) | 2010-06-03 | — | — | US | disclosed |
| EP-2173777-A1 | AQUEOUS DISPERSIONS CONTAINING CRYSTALLISABLE BLOCK COPOLYMERS | DSM IP Assets B.V. (NL) | 2010-04-14 | — | — | EP | disclosed |
| EP-2132243-A1 | AQUEOUS OLIGOMER / POLYMER EMULSION WITH CATIONIC FUNCTIONALITY | DSM IP Assets B.V. (NL) | 2009-12-16 | — | — | EP | disclosed |
| WO-2009016239-A1 | AQUEOUS DISPERSIONS CONTAINING CRYSTALLISABLE BLOCK COPOLYMERS | DSM IP ASSETS B.V. (NL) | 2009-02-05 | — | — | WO | disclosed |
| WO-2008122576-A1 | AQUEOUS OLIGOMER / POLYMER EMULSION WITH CATIONIC FUNCTIONALITY | DSM IP ASSETS B.V. (NL) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205275-A1 | POLYMERIC IRON BINDING COMPOSITIONS AND METHODS OF USE FOR TREATING DISEASES ASSOCIATED WITH EXCESS DAMAGING REACTIVE IRON | SLC40A1, TFRC, FANCF | ALDH1A1 1463/4885CYP2D6 3690/4885HPGD 539/4885 |
| US-11059785-B2 | Polymeric metal chelating compositions and methods of preparing same for controlling growth and activities of living cells and organisms | PICALM, HMBS, TFRC | ALDH1A1 3416/4885CYP2D6 4796/4885HPGD 131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.